SAN DIEGO, August 24, 2006 — Conatus Pharmaceuticals Inc. today announced that it has relocated the corporate operations to 4365 Executive Drive, Suite 200, San Diego, CA 92121. The main telephone number is 858-558-8130 and the facsimile number, 858-558-8920. “We are pleased to have secured a premium location in the University Towne Centre section of […]

SAN DIEGO, October 25, 2011 — Conatus Pharmaceuticals Inc. announced today the termination of its Phase 2 clinical trial of CTS-1027 in HCV patients. This decision follows reports of laboratory abnormalities and adverse events in a subset of clinical trial participants. The top priority of Conatus is patient safety, and the Company has made the […]

SAN DIEGO, November 1, 2011 — Conatus Pharmaceuticals Inc. announced today the appointment of Gary Craig Burgess, M.B., Ch.B. MMed, as Senior Vice President and Chief Medical Officer effective immediately. In this newly created position, Dr. Burgess will oversee all of the company’s clinical development activities. “I am delighted to welcome Gary to the Conatus […]

SAN DIEGO, November 5, 2007 — Conatus Pharmaceuticals Inc. today reported positive preclinical results on its lead compound, CTS-1027 in multiple models of hepatitis, an inflammatory liver disease. The results were presented in a poster session today at the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. CTS-1027 significantly reduced liver […]

SAN DIEGO, December 20, 2007 — Conatus Pharmaceuticals Inc. today announced the initiation of a clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection in patients who have failed the approved standard of care treatments. The oral, small molecule drug candidate, CTS-1027, is being […]

SAN DIEGO, January 28, 2010 — Conatus Pharmaceuticals Inc. announced today the initiation of a Phase II clinical trial evaluating CTS-1027 in combination with pegylated interferon (Pegasys®) and ribavirin (Copegus®) in refractory HCV patients. Antiviral activity, safety and tolerability of the triple combination will be assessed after up to 48 weeks of therapy. “There is […]

SAN DIEGO, March 11, 2011 — Conatus Pharmaceuticals Inc. today announced the acceptance of two poster presentations of Phase 2 clinical trial data of CTS–1027 for the treatment of hepatitis C virus–infected patients at the 46th annual meeting of the European Association for the Study of the Liver (EASL) to be held in Berlin, Germany, […]

SAN DIEGO, June 24, 2009 — Conatus Pharmaceuticals Inc. announced today the initiation of a second Phase 2 clinical trial with a novel drug candidate for the treatment of liver disease associated with Hepatitis C Virus (HCV) infection. The trial will enroll patients for whom treatment with approved standard of care treatments is not currently […]

SAN DIEGO, July 12, 2012 — Conatus Pharmaceuticals Inc. announced today the appointment of Mark F. Morris as Head of Biostatistics effective immediately. In this newly created position, Mr. Morris will oversee the statistical design of the company’s human clinical trials. “Mark provides an enormous amount of technical expertise in statistical design and analysis,” said […]

SAN DIEGO, February 11, 2011 — Conatus Pharmaceuticals Inc. today announced the closing of a $20 million Series B Preferred Stock private placement financing. This financing was led by new investor, AgeChem Venture Fund of Montreal, Canada, and included participation by existing investors; Aberdare Ventures, Advent Venture Partners, Bay City Capital, Gilde Healthcare Partners, and […]